BioMarin Pharmaceutical Inc. (LON:0HNC)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 7.93B +4.3% |
| Revenue (ttm) | 2.57B +11.2% |
| Net Income | 55.00M -88.9% |
| EPS | 0.29 -88.9% |
| Shares Out | n/a |
| PE Ratio | 144.26 |
| Forward PE | 9.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122 |
| Open | 56.56 |
| Previous Close | 56.72 |
| Day's Range | 54.98 - 57.00 |
| 52-Week Range | 49.39 - 70.85 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 27, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of BioMarin (BMRN) with a Buy rating and $88 price target The firm views the company as a turnaround story. Management changes that took…
BioMarin price target raised to $114 from $111 at Barclays
Barclays raised the firm’s price target on BioMarin (BMRN) to $114 from $111 and keeps an Overweight rating on the shares as part of a Q3 earnings preview. BioMarin “sounds…
BioMarin to present ‘encouraging’ results from studies of voxzogo at ASBMR
BioMarin (BMRN) Pharmaceutical announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting in Boston, including results from studies…
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewsw...
BioMarin names Cara Bauer as Chief People Officer
BioMarin (BMRN) Pharmaceutical announced that Cara Bauer, Ph.D., has been named Executive Vice President, Chief People Officer. Bauer will assume responsibility for the company’s Human Resources organ...
BioMarin Appoints Cara Bauer as Chief People Officer
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ --...
BioMarin reports five-year Pompe disease data showing durable motor function
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new...
BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA
BioMarin (BMRN) Pharmaceutical announced new data evaluating the efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease were presented at the 31st Annual Congress of the World Muscle…
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) tod...
Profluent Partners With BioMarin to Design Novel Medicines Using AI
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $BMRN--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapi...
BioMarin price target lowered to $97 from $98 at BMO Capital
BMO Capital lowered the firm’s price target on BioMarin (BMRN) to $97 from $98 and keeps an Outperform rating on the shares after the company discontinued development of Voxzogo in…
BioMarin to discontinue development of Voxzogo for children with Noonan syndrome
In a regulatory filing, BioMarin (BMRN) Pharmaceutical disclosed its decision to discontinue development of Voxzogo for children with Noonan syndrome. “BioMarin made this decision after assessing a nu...
BioMarin Pharmaceutical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Integration of recent acquisitions is driving new growth, with Amicus and Alesta expanding the pipeline and financial strength. Key products like VOXZOGO, GALAFOLD, and POMBILITI + OPFOLDA are set for significant growth, while operational synergies and deleveraging targets are on track.
BioMarin names Robert Plenge, M.D., Ph.D., to board of directors
BioMarin Pharmaceutical (BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company’s Board of Directors, effective September 10. Dr. Plenge is Executive Vice President,...
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.
BioMarin Pharmaceutical Transcript: Citigroup’s Biopharma Back to School Summit 2026
Key priorities include expanding blockbuster therapies and leveraging recent acquisitions for growth. Pipeline advances feature VOXZOGO's strong performance, new indications, and innovative assets like BMN 333 and ALE-01. AI tools are streamlining R&D and patient identification.
BioMarin Pharmaceutical Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Significant portfolio expansion and strong financial growth were highlighted, with new assets from the Amicus acquisition expected to drive substantial revenue and EPS accretion. VOXZOGO remains a key growth driver, while promising pipeline developments and global expansion underpin long-term strategy.
BioMarin Pharmaceutical Transcript: Wells Fargo 21st Annual Healthcare Conference
Metabolic and skeletal franchises are driving robust growth, with VOXZOGO and Amicus products expanding globally. The pipeline is advancing with promising data in hypochondroplasia, new deals, and upcoming readouts for BMN 333, BMN 351, and FSGS. Strategic settlements and international expansion underpin future revenue.
BioMarin reports new data from Phase 3 CANOPY-HCH-3 study
BioMarin (BMRN) Pharmaceutical announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO, or vosoritide, in children with hypochondroplasia were published in New England Journal of Med...
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual ...
BioMarin to Participate in Upcoming Investor Conferences
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, Septem...
BioMarin completes agreement to acquire Alesta Therapeutics
BioMarin Pharmaceutical (BMRN) said that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen BioMarin’s skeletal conditions portfolio, addin...
BioMarin Announces Close of the Alesta Therapeutics Acquisition
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today...
BioMarin price target raised to $86 from $85 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on BioMarin (BMRN) to $86 from $85 and keeps an Overweight rating on the shares after the company reached a settlement with Ascendis…
BioMarin price target raised to $90 from $88 at Piper Sandler
Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on BioMarin (BMRN) to $90 from $88 and keeps an Overweight rating on the shares on news of a…